论文部分内容阅读
AIM To compare therapeutic responses of a vasculardisrupting-agent,combretastatin-A4-phosphate(CA4P),among hepatocellular carcinomas(HCCs)and implanted rhabdomyosarcoma(R1)in the same rats by magneticresonance-imaging(MRI),microangiography and histopathol